The all-in-one platform to find and track your stocks and investments
Discover the features
Statistics
Market Cap
960 million
PE Ratio
5.52 x
Beta (volatility)
1.33
Earnings Per Share
2.21
About
ISIN : US21900C3088
It primarily focuses on the...
Price
Performance Comparison
| CorMedix Inc | |
|---|---|
| 1 year return |
+44 %
|
| 5 years return |
+57 %
|
Valuation
| Price to Book | Payout ratio | PEG Ratio |
|---|---|---|
| 2.57 | 0 % | 0.00 |
| Price to Sales | Price / FCF | E.V.R. |
|---|---|---|
| 22.07 | -14.18 | 4.92 |
Price–Earnings Ratio History
The Price–Earnings Ratio history is not available for this stock.
Dividend History
It looks like no dividends is being distributed for this stock...
Number of Outstanding Shares
Financials
Year-over-Year growth
Profitability
Health
News
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
12/31/2025
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
12/31/2025
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
12/26/2025
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
12/24/2025
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
12/24/2025
CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies
12/23/2025
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
12/23/2025
AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)
12/23/2025
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
12/22/2025
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
12/19/2025
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
12/18/2025
PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study
12/18/2025
Create a portfolio & add this stock
Add this stock and others to your own virtual portfolio and get personalised information : total annual dividends & total value, sectors breakdown, etc.
Privacy Policy • Terms and Conditions
© Copyright 2020-2026 Epsylia OÜ - All rights reserved
Moning is a platform that does not manage any funds and is purely educational. We do not provide any investment advice.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.
The data presented comes from different providers and may contain errors. We encourage you to always verify information through other sources.
Any financial investment involves risks including partial or total loss of capital.